For Tina, finally getting a diagnosis of Sjögren’s was a relief. Tina Aswani Omprakash’s hospital bedside table was crowded with an unusual collection of items she regularly used to combat dryness ...

At Novartis, we celebrate life and recognize moments that matter. One of the most life changing moments our people experience is becoming a parent and welcoming new life into their lives. All Novartis ...

Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU ...

Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9 million ...

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is ...

Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...

Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by ...

Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...